MedTrace Logo

Study Evaluating the Safety and Feasibility of Platelet-rich Plasma to Treat Facetogenic Low Back Pain

NCT05250947 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2024-07-17

No results posted yet for this study

Summary

This study is being done to assess the safety of using the Angel Concentrated Platelet Rich Plasma System to process Platelet Rich Plasma (PRP) to treat arthritis of the low back (lumbar spondylosis).

Conditions

  • Lumbar Spondylosis

Interventions

DEVICE

Angel® Concentrated Platelet Rich Plasma System

Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.

DRUG

Platelet Rich Plasma

6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint

Sponsors & Collaborators

  • Matthew Pingree

    lead OTHER

Principal Investigators

  • Matthew Pingree, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-05
Primary Completion
2024-05-20
Completion
2024-05-20
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05250947 on ClinicalTrials.gov